INSPInspire Medical Systems, Inc.
Price
-9.0%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growing in the filings, the market undecided.
We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Inspire Medical Systems, Inc. (INSP) reported revenue of $201M in Q2 2026 (quarter ended Jun 30, 2026), down 7.6% from the same quarter a year earlier. That came with a gross margin of 85% and net income of $314K (0.2% of revenue). For the full year FY2025, revenue was $912M (+14% year on year) and net income $145M. Its largest region in Q2 2026 was United States at $187M, 93% of the disclosed total, well ahead of Non Us at 6.6%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 24, 2026On July 20, 2026, the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Michael H. Carrel to the Board, effective immediately.Director or officer change · Form 8-K
- Jul 22, 2026On July 16, 2026, Casey Tansey, a member of the Board of Directors (the “Board”) of Inspire Medical Systems, Inc. (the “Company”), notified the Company of his decision to retire from the Board (and the committees on which he serves) and not stand for re-election at the Company’s 2027 Annual Meeting of Stockholders …Director or officer change · Form 8-K
- Feb 11, 2026The Company intends to put forth a proposal at the Company’s annual meeting of stockholders to be held in 2026 (the “2026 Annual Meeting”) to amend its Seventh Amended and Restated Certificate of Incorporation in order to declassify its Board of Directors (the “Board”) and provide for the annual election of directors …Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $200.6MThe company’s own SEC segment disclosure.
- United States$187.3M93%
- Non Us$13.3M7%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.